Cna Financial Corp Erasca, Inc. Transaction History

Cna Financial Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$5.82 - $10.68 $12,629 - $23,175	-2,170 Reduced 10.16%	19,197 $150,000
Q2 2022 Aug 09, 2022	BUY	$4.58 - $8.72 $19,648 - $37,408	4,290 Added 25.12%	21,367 $119,000
Q4 2021 Feb 11, 2022	BUY	$12.51 - $22.75 $36,779 - $66,885	2,940 Added 20.8%	17,077 $266,000
Q3 2021 Nov 12, 2021	BUY	$17.43 - $24.34 $246,407 - $344,094	14,137 New	14,137 $300,000

117

74.3M

7.1K

40.1K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $265M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of Cna Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Cna Financial Corp with notifications on news.